Want to see HK:1763 full AI Analyst Report?
Top Page
China Isotope & Radiation Corp.
(1763)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$12.00
â–¼(-48.98% Downside)
Action:Reiterated
Date:10/23/26
The score reflects mixed fundamentals led by solid operating profitability and a generally stable balance sheet, but weighed down by a 2025 revenue contraction, thin net margins, and volatile free cash flow. Technicals are a significant drag due to a strong downtrend across key moving averages and negative MACD, while valuation support (low P/E and ~3.83% yield) partially offsets these risks.
Positive Factors
Operating Profitability
Strong gross and operating margins show that the irradiation services model retains meaningful underlying profitability despite weaker revenue. This operating resilience can support reinvestment, customer service capacity, and earnings stability over the next several quarters.
Negative Factors
Revenue Contraction
The reversal from several years of growth to a material 2025 revenue decline signals weaker recent demand or activity across the business. Unless growth resumes, lower scale can restrict operating leverage, investment capacity, and the company’s ability to expand earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Operating Profitability
Strong gross and operating margins show that the irradiation services model retains meaningful underlying profitability despite weaker revenue. This operating resilience can support reinvestment, customer service capacity, and earnings stability over the next several quarters.
Read all positive factors
China Isotope & Radiation Corp. (1763) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.76B
Dividend Yield4.2%
Average Volume (3M)94.22K
Price to Earnings (P/E)10.4
Beta (1Y)0.70
Revenue Growth-4.92%
EPS Growth-19.51%
CountryHK
Employees3,655
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.96
Shares Outstanding79,968,800
10 Day Avg. Volume148,780
30 Day Avg. Volume94,215
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)1.11
Price to Sales (P/S)0.83
P/FCF Ratio-119.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.76
Revenue Forecast (FY)HK$9.04B
China Isotope & Radiation Corp. Business Overview & Revenue Model
Company Description
China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout ...
China Isotope & Radiation Corp. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
70
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.14B | 7.00B | 7.57B | 6.63B | 6.15B | 5.14B |
| Gross Profit | 3.53B | 3.52B | 3.68B | 3.48B | 3.51B | 3.24B |
| EBITDA | 1.22B | 1.18B | 1.31B | 1.22B | 1.10B | 940.09M |
| Net Income | 305.95M | 318.95M | 406.64M | 370.97M | 392.27M | 335.75M |
Balance Sheet | ||||||
| Total Assets | 16.08B | 15.72B | 14.77B | 13.19B | 11.69B | 10.47B |
| Cash, Cash Equivalents and Short-Term Investments | 2.55B | 2.59B | 2.63B | 2.94B | 2.93B | 2.79B |
| Total Debt | 2.86B | 2.73B | 2.57B | 1.70B | 903.86M | 856.63M |
| Total Liabilities | 7.73B | 7.59B | 7.02B | 6.05B | 5.13B | 4.44B |
| Stockholders Equity | 5.31B | 5.23B | 5.01B | 4.69B | 4.47B | 4.18B |
Cash Flow | ||||||
| Free Cash Flow | 242.42M | -48.41M | 142.48M | -812.66M | 328.66M | 366.59M |
| Operating Cash Flow | 826.76M | 538.34M | 142.48M | 84.96M | 862.66M | 794.31M |
| Investing Cash Flow | -392.48M | -348.92M | -564.81M | -429.88M | -506.62M | -907.36M |
| Financing Cash Flow | -432.84M | -168.80M | 499.70M | 484.37M | -291.50M | -97.44M |
China Isotope & Radiation Corp. Technical Analysis
Negative
23.52
Price Trends
13.87
Negative
15.50
Negative
17.65
Negative
Market Momentum
-0.51
Negative
42.79
Neutral
71.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1763, the sentiment is Negative. The current price of 23.52 is above the 20-day moving average (MA) of 12.38, above the 50-day MA of 13.87, and above the 200-day MA of 17.65, indicating a bearish trend. The MACD of -0.51 indicates Negative momentum. The RSI at 42.79 is Neutral, neither overbought nor oversold. The STOCH value of 71.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1763.
China Isotope & Radiation Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$5.01B | 17.60 | 9.20% | 5.45% | 10.27% | 79.65% | |
67 Neutral | HK$4.71B | 21.31 | 10.38% | 1.74% | 3.83% | -27.04% | |
59 Neutral | HK$6.35B | 98.22 | 1.71% | ― | 0.75% | -20.22% | |
56 Neutral | HK$3.76B | 10.38 | 5.81% | 4.20% | -4.92% | -19.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
46 Neutral | HK$11.65B | 31.23 | 6.07% | 0.06% | -3.62% | ― |
* Healthcare Sector Average
HK:1763
China Isotope & Radiation Corp.
11.74
-6.99
-37.31%
HK:0853
MicroPort Scientific
6.08
-6.03
-49.83%
HK:1302
LifeTech Scientific Corporation
1.47
-0.54
-26.87%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
7.39
-10.94
-59.70%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-4.67
-78.49%
HK:2172
MicroPort NeuroTech Limited
8.06
-3.70
-31.47%
China Isotope & Radiation Corp. Corporate Events
China Isotope & Radiation Updates Interim Dividend and Tax Terms for H Shareholders
Oct 21, 2026
China Isotope Radiation Corporation, a Hong Kong-listed supplier of isotopes and radiation-related products for medical and industrial use, operates in a specialized segment of the healthcare and technology markets. Its H share listing broadens i...
China Isotope & Radiation Unit Plans 20% Capital Increase via CBEX Tender
Oct 21, 2026
China Isotope Radiation Corporation has received board approval to pursue a capital increase at its non-wholly-owned subsidiary Chengdu Gaotong Isotope Co., Ltd., equivalent to 17,645,851 new shares or a 20% equity interest. As CNGT is a state-co...
China Isotope & Radiation Wins Strong Shareholder Backing at 2026 Extraordinary Meeting
Oct 21, 2026
China Isotope Radiation Corporation reported the poll results of its second extraordinary general meeting of 2026, confirming that the meeting was validly convened and heavily attended, with shareholders representing about 76% of voting shares pr...
China Isotope & Radiation Details Board and Committee Structure
Oct 21, 2026
China Isotope Radiation Corporation has disclosed the current composition of its board of directors, detailing executive, non-executive and independent non-executive members and their roles. The board is led by executive director and chairman Xia...
CIRC Subsidiary Wins Approval for New Urea 13C Breath Test Kit
Oct 9, 2026
China Isotope Radiation Corporation announced that its subsidiary Shenzhen Zhonghe Headway Bio-Sci Tech has obtained a Drug Registration Certificate from the National Medical Products Administration for its independently developed 50mg Urea 13C ...
China Isotope & Radiation Clarifies Compliance on Connected Transactions in 2025 Report
Oct 9, 2026
China Isotope Radiation Corporation has issued a supplemental announcement to its annual report for the year ended 31 December 2025, clarifying the treatment of related party transactions. The company stated that all related party transactions di...
China Isotope & Radiation Calls October EGM on Fund Investment, Dividend and Share Mandate
Sep 29, 2026
China Isotope Radiation Corporation has convened its second extraordinary general meeting of 2026 for 21 October in Beijing, bringing together domestic and H share investors under its dual-share structure. The meeting underscores the company̵...
China Isotope & Radiation Corp. Moves to Add Nuclear Veteran Li Penghui to Board
Sep 29, 2026
China Isotope Radiation Corporation has proposed appointing its current general manager, 54-year-old nuclear engineer Li Penghui, as an executive director for the fourth session of the board, subject to shareholder approval at an upcoming extraor...
China Isotope & Radiation Gains FDA Clearance for Lu-177 Nuclear Medicine Ingredient
Sep 22, 2026
China Isotope Radiation Corporation has announced that its subsidiary Chengdu Gaotong Isotope has obtained U.S. FDA clearance for its drug master file covering Lu-177 active pharmaceutical ingredients, formally activating the DMF number for use b...
China Isotope & Radiation Delays EGM and Reschedules Interim Dividend Timetable
Sep 21, 2026
China Isotope Radiation Corporation has postponed its extraordinary general meeting to 21 October 2026 to allow more time to finalise information for a shareholder circular on its proposed interim dividend and a connected transaction involving th...
China Isotope & Radiation Updates 2026 Interim Dividend Schedule and Tax Terms
Sep 21, 2026
China Isotope Radiation Corporation has updated the timetable for its interim cash dividend for the six months ended 30 June 2026, maintaining a declared payout of RMB 0.0994 per share for the financial year ending 31 December 2026. Key dates now...
China Isotope & Radiation Joins CNNC-Led Nuclear Technology Investment Fund
Aug 28, 2026
China Isotope Radiation Corporation has agreed to join a new CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund as a limited partner alongside several state and local investment entities, with CNNC Fund acting as general pa...
China Isotope & Radiation Releases Unaudited Interim Results for First Half of 2026
Aug 28, 2026
China Isotope Radiation Corporation has released its unaudited interim results for the six months ended June 30, 2026, providing condensed consolidated financial statements and comparative figures for the same period in 2025. The company will als...
China Isotope & Radiation Declares Interim Dividend and Details Tax Treatment for H-Shareholders
Aug 28, 2026
China Isotope Radiation Corporation has declared an interim ordinary dividend of RMB 0.0994 per share for the six months ended 30 June 2026, for the financial year ending 31 December 2026. The dividend, subject to shareholder approval on 29 Septe...
China Isotope & Radiation Names Nuclear Veteran Li Penghui as General Manager
Aug 28, 2026
China Isotope Radiation Corporation announced that executive director and general manager Zhang Junqi has resigned from all positions, including his roles on the board’s strategy and science and technology innovation committees, citing an a...
China Isotope & Radiation Updates Board and Committee Roles
Aug 28, 2026
China Isotope Radiation Corporation has released an updated list of its board members and detailed their roles across six key board committees, clarifying the division of responsibilities between executive, non-executive, and independent non-exec...
China Isotope & Radiation Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 14, 2026
China Isotope Radiation Corporation is a Hong Kong-listed joint stock company in the nuclear technology and isotope segment, supplying radioisotope products and radiation services for medical, industrial and research uses in China and the wider A...
China Isotope & Radiation Sets Ambitious Revenue Outlook for Nuclear Medicine JV
Aug 4, 2026
China Isotope Radiation Corporation has released detailed financial forecasts for its planned Nuclear Medicine Development Center, tied to a connected transaction establishing a joint venture. The center’s principal-business revenue is proj...
China Isotope & Radiation Forms Nuclear Medicine Joint Venture CNNC Fuzhi
Jul 28, 2026
China Isotope Radiation Corporation has agreed to form a joint venture, CNNC Fuzhi, with CNNC Zhejiang Science and Technology Innovation, setting its registered capital at RMB50 million. The company will contribute RMB45 million mainly via cash a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.